Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: allogeneic T-cell therapies - Adaptimmune/Universal Cells

Next Previous
Search
Drug Profile

Research programme: allogeneic T-cell therapies - Adaptimmune/Universal Cells

Latest Information Update: 23 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; Universal Cells
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Mar 2023 Allogeneic T-cell therapies is still in preclinical trials for Cancer in USA
  • 06 Mar 2023 Adaptammune and Universal cells terminates its collaboration and licence agreement for the developement of allogeneic T-cell therapies
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top